Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
Internal Medicine Journal2016Vol. 46(9), pp. 1054–1062
Citations Over TimeTop 10% of 2016 papers
Peter G. Gibson, Helen K. Reddel, Vanessa M. McDonald, Guy B. Marks, Christine Jenkins, Andrew Gillman, John W. Upham, Michael Sutherland, Janet Rimmer, Francis Thien, G. P. Katsoulotos, Matthew Cook, Ian A. Yang, Constance H. Katelaris, Simon Bowler, David Langton, Paul D. Robinson, Casey M. Wright, V. Yozghatlian, Scott Burgess, Pathmanathan Sivakumaran, Adam Jaffé, Jeffrey J. Bowden, Peter Wark, Kwok Yan, Vicky Kritikos, Matthew Peters, Mark Hew, A. Aminazad, Michael Bint, Michael Guo
Abstract
Australian patients with severe allergic asthma report a high disease burden and have extensive comorbidity. Symptomatic response to omalizumab was high despite significant comorbid disease. Omalizumab is an effective targeted therapy for severe allergic asthma with comorbidity in a real-life setting.
Related Papers
- → Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria(2015)193 cited
- → Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments(2015)27 cited
- → Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience(2015)13 cited
- → P170 Concomitant omalizumab and cyclosporine for chronic idiopathic urticaria: a case series(2017)3 cited
- → P154 Biomarkers which may predict response to omalizumab in chronic urticaria: serum IGE and CD203C(2017)1 cited